Challenge:
Our client, a mid-cap pharma, was planning to extend its portfolio in the gastrointestinal (GI) disease space. It was considering microbiome-based approaches, specifically live biotherapeutic products (LBP), technologies with which it was not familiar. Alacrita's assignment was in two parts. Firstly a review of investment trends in BP development companies and secondly an analysis of four speciality GI indications.
Solution:
The analysis was conducted within a two-week timeframe, drawing on secondary research including subscription databases, Alacrita's proprietary databases, web searches and scientific literature. We provided an analysis of funding in the microbiome space over the past 10 years, covering the peaks and troughs of interest in the space. For each of the four specific indications, we used similar sources to map the epidemiology, unmet need, current standard of care for each indication and projected treatment trends.
Due Diligence Consulting
Alacrita due diligence consultants have been a trusted DD source for close to fifteen years, conducting assignments for large pharma, biotech, universities and investors. Every due diligence we perform is underpinned by our ability to incorporate individuals into each project who have the exact matching expertise required for a complete, thorough and accurate assessment.